Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.72 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.72 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.59 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448612 | 1.00 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL452161 | 1.00 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL450568 | 0.88 | S1PR1 (0.75) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL449215 | 0.88 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL450092 | 0.88 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL451017 | 0.88 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL451921 | 0.87 | S1PR1 (0.71) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL450481 | 0.87 | S1PR1 (0.70) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL4963049 | 0.85 | S1PR1 (0.77) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL4961705 | 0.85 | S1PR1 (0.77) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | claimed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | S1PR1 1/4885S1PR3 2/4885S1PR4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.